A large provider of haemodialysis services wanted to increase the market share of one of their products. They requested Panaxea 1) to develop a health economic value story to secure global reimbursement for this technology; 2) and to develop a model incorporating both a cost-effectiveness and budget impact analysis to support this dossier. A value story concerning the effectiveness of both treatment modalities was written following an extensive literature review. Based on this we developed a Markov model to project costs, reimbursement and adverse events over a time horizon of five years. The model allows all input parameters to be changed, to make the model match closely to the decision makers population characteristics, reimbursement and cost patterns.